Skip to content

Assessment of skin irritability after using a health product

ORC_115312_EN24-0384-01 - Assessment of Primary Dermal Irritability, Cumulative Dermal Irritability and Dermal Sensitization (HRIPT)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-5f7x539
Enrollment
Unknown
Registered
2024-10-22
Start date
2025-02-03
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Accidental Injuries

Interventions

Sponsors

Medcin Instituto da Pele LTDA
Lead Sponsor
Helianto Farmacêutica Ltda
Collaborator

Eligibility

Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Participants of both sexes; aged 18 to 70 years; skin of the application region integrates; agreeing to follow the test procedures and to attend the clinic on the days and times determined for medical evaluations and for application and reading of dressings; understanding, consent and signing of the Free and Informed Consent Term (ICF)

Exclusion criteria

Exclusion criteria: Pregnancy or risk of pregnancy and/or lactation; use of anti-inflammatory drugs and/or immunosuppressive drugs for up to three months before selection; immunosuppression by drugs or active disease; decompensated endocrinopathies; Personal history of atopy; intense sun exposure or tanning sessions up to 15 days before the assessment or during the study period; expect intense exposure to sunlight or tanning sessions during the study period; provision of bathing in the sea, swimming pool or sauna during the study; practice of water sports during the study; dermographism; use of oral or topical treatment with vitamin A acid and/or its derivatives up to 1 week before the start of the study; aesthetic and/or dermatological treatment on the body within 03 weeks before selection; scheduled vaccination during the study period or up to 3 weeks before selection; history of sensitization, irritation or photosensitization to topical products; active skin pathologies (local and/or disseminated) that may interfere with the study results; skin reactivity; use of new drugs/cosmetics during the study; previous participation in studies with the same product; congenital or acquired immunodeficiency; relevant medical history or current evidence of alcohol or other drug abuse; known or suspected history of intolerance to any ingredient in study products (test or comparative product); history of non-adherence or unwillingness to adhere to the study protocol; employees of Medcin or the sponsoring company involved in the study, or a close family member of an employee involved in the study; other conditions considered by the researcher as reasonable for disqualification from participating in the study

Design outcomes

Primary

MeasureTime frame
Prove the absence of irritation reactions (primary and accumulated dermal irritation) and allergy (dermal sensitization) of the investigational product in the studied population through the comparability test

Secondary

MeasureTime frame
No secondary outcomes are expected

Countries

Brazil

Contacts

Public ContactFlavia Addor

Medcin Instituto da Pele LTDA

flavia@medcinonline.com.br+55(11)36835366

Outcome results

None listed

Source: REBEC (via WHO ICTRP)